Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
Fundación Hipercolesterolemia Familiar
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Fundación Hipercolesterolemia Familiar (32)
2024
-
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study
American Journal of Preventive Cardiology, Vol. 17
-
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study
Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206
-
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study
Atherosclerosis, Vol. 393
-
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652
2023
-
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study
Circulation, Vol. 147, Núm. 19, pp. 1436-1443
-
Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study
European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328
2022
-
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort
European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801
-
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
Current Atherosclerosis Reports, Vol. 24, Núm. 6, pp. 427-434
2021
-
Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia
Nutrition, Metabolism and Cardiovascular Diseases, Vol. 31, Núm. 7, pp. 2014-2022
-
Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study
Atherosclerosis, Vol. 317, pp. 52-58
-
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience
Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592
-
High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients
Cardiovascular Research, Vol. 117, Núm. 1, pp. 109-122
-
Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia
European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211
-
The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia
JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424
2020
-
Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry
Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834
-
Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 40, Núm. 10, pp. 2508-2515
2019
-
Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: The SAFEHEART study
Public Health Nutrition, Vol. 22, Núm. 8, pp. 1433-1443
-
Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia from different countries
European Journal of Clinical Nutrition, Vol. 73, Núm. 12, pp. 1622-1625
-
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study
Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996
-
Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia
Atherosclerosis, Vol. 286, pp. 40-45